← Human Trials & Peer-Reviewed Studies
A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients.
Plain-language guide to PMID 30197501 (2018): double-blind randomized controlled trial of Angiotensin II in 182 patients.
Key Facts
- PMID
- 30197501
- Journal
- Drug design, development and therapy
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Derosa G et al. (5 authors)
- DOI
- 10.2147/DDDT.S151449
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II, published as a randomized controlled trial.
The aim of this study was to evaluate the effects of canrenone compared to hydrochlorothiazide (HCTZ) added to angiotensin II receptor blockers (ARBs) on glycemia, lipid profile, potassium, aldosterone and renal function in patients with hypertension and type 2 diabetes mellitus.
Who Took Part
The abstract describes 182 patients taking part.
PubMed indexes the participants as middle-aged adults, both men and women.
The study enrolled 182 Caucasian patients with hypertension and type 2 diabetes mellitus.
The following parameters were considered at 6 and 12 months: BP, body weight, body mass index (BMI), fasting plasma glucose (FPG), post-prandial glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin (HOMA-IR), lipid profile, potassium, plasma aldosterone, urine albumin excretion rate and estimated glomerular filtration rate (eGFR).
How the Study Was Run
The researchers set it up as a randomized and double-blind study.
The patients were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.
As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.
What Was Measured
The subject headings attached to it are Angiotensin Receptor Antagonists, Antihypertensive Agents, Canrenone, Diabetes Mellitus, Type 2 and Hydrochlorothiazide.
The authors tagged it with the keywords metabolism and type 2 diabetes mellitus.
What This Means in Plain Language
The paper is a randomized and double-blind study of Angiotensin II in 182 patients.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2018 (Drug design, development and therapy), a journal based in New Zealand.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.